New targets for antibody therapy of pediatric B cell lymphomas

Annelies van Vuren, Friederike Meyer-Wentrup

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

2 Citaten (Scopus)


Antibody therapy has become standard of care for adult B cell lymphoma patients. It is a potentially less toxic and more targeted approach for lymphoma therapy and should therefore be applied to treat pediatric B cell lymphoma patients as well. In pediatric lymphoma patients, however, clinical experience with monoclonal antibodies is very limited. This is in part due to smaller patient numbers and very good outcome with conventional chemotherapy. In addition, pediatric patient and lymphoma biology differ significantly from that found in adults often precluding extrapolation of the adult experience to children. This review focuses on targeting pediatric B cell lymphoma with monoclonal antibody therapy. The special characteristics of B cell lymphomas found in children are reviewed and six potential new lymphoma target antigens are discussed.

Originele taal-2Engels
Pagina's (van-tot)2158-2163
Aantal pagina's6
TijdschriftPediatric Blood and Cancer
Nummer van het tijdschrift12
StatusGepubliceerd - 1 dec. 2014
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'New targets for antibody therapy of pediatric B cell lymphomas'. Samen vormen ze een unieke vingerafdruk.

Citeer dit